论文部分内容阅读
80名无症状慢活肝患者平均随访6个月,经复查肝活检,证实了慢活肝的诊断,其中15例合伴有肝硬化现象;13例肝小叶界板有中或大范围的损害;12例在随访期间死亡(7例死于肝衰竭,5例死于无关原因)。5年予计生存率91%;10年生存率81%。3例在随访期间发生腹水、肝性脑病或食道静脉曲张。为证实激素的疗效,对18例患者使用12毫克甲基强地松龙一年疗法,11例用安慰剂对照观察,随机分组。治疗开始及12个月后分别测定血清门冬转氨酶水平进行对比,开始时激素组有所下降,但12月后两组平均值相近,其他肝功能试验结果变化不大,没有患者发展为症状性肝病。用激素组
Eighty asymptomatic patients with chronic liver failure were followed up for an average of 6 months. Confirmed liver biopsy confirmed the diagnosis of slow-living liver, of which 15 cases were associated with cirrhosis. Thirteen cases of hepatic lobule demarcation were moderate or extensive ; 12 died during follow-up (7 died of liver failure and 5 died of unrelated causes). 5-year survival rate of 91%; 10-year survival rate of 81%. Three patients developed ascites, hepatic encephalopathy or esophageal varices during follow-up. To confirm the efficacy of the hormone, 12 patients were treated with 12 mg of methylprednisolone for one year and 11 patients were treated with placebo and randomized. At the beginning of treatment and 12 months after the determination of serum aspartate aminotransferase levels compared to the beginning of the hormone group decreased, but after 12 months the average was similar, the other liver function test results did not change, no patient developed symptomatic Liver disease. With hormone group